PPARγ agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance

Pharmacological Research

Volumn 55, Issue 5, 2007, Pages 400-407

  Gaikwad, Anil Bhanudas ^a   Viswanad, Bhoomi ^a   Ramarao, Poduri ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Angiotensin II; Insulin resistance; PPAR ; Thoracic aorta and hypertension

Indexed keywords

ANGIOTENSIN II; CHOLESTEROL; GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; STREPTOZOCIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN II; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; DIETARY FATS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; PPAR GAMMA; PREDIABETIC STATE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; STREPTOZOCIN; THIAZOLIDINEDIONES; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 34247100091     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.01.015     Document Type: Article

References (48)

1. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 5 (2004) H1597-H1602
2. Lavoie J.L., and Sigmund C.D. Overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 144 (2003) 2179-2183
3. Srivastava A.K. High glucose-induced activation of protein kinase signaling pathways in vascular smooth muscle cells: a potential role in the pathogenesis of vascular dysfunction in diabetes. Int J Mol Med 9 (2002) 85-89
4. Schiffrin E.L., Amiri F., Benkirane K., Iglarz M., and Diep Q.N. Peroxisome proliferator-activated receptors: vascular and cardiac effects in hypertension. Hypertension 42 4 (2003) 664-668
5. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 19 3 (1999) 546-551
6. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 83 11 (1998) 1097-1103
7. Srinivasan K., Patole P.S., Kaul C.L., and Ramarao P. Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol 26 5 (2004) 327-333
8. Srinivasan K., Viswanad B., Asrat L., Kaul C.L., and Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52 4 (2005) 313-320
9. Arun K.H., Kaul C.L., and Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats. Cardiovasc Res 65 2 (2005) 374-386
10. Viswanad B., Srinivasan K., Kaul C.L., and Ramarao P. Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res 53 3 (2006) 209-215
11. Arun K.H., Kaul C.L., and Ramarao P. High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta. Pharmacol Res 50 6 (2004) 561-568
12. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 1 (1951) 265-275
13. Karin J.D., and Cooper M.E. Hypertension and diabetes. Curr Opin Nephrol Hypertens 11 (2002) 221-228
14. Ghatta S., and Ramarao P. Increased contractile responses to 5-hydroxytryptamine and angiotensin II in high fat diet fed rat thoracic aorta. Lipids Health Dis 3 19 (2004) 19
15. Randle P.J., Garland P.B., Hales C.N., and Newsholme E.A. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1 (1963) 785-789
16. Belfiore F., and Iannello S. Insulin resistance in obesity: metabolic mechanisms and measurement methods. Mol Genet Metab 65 2 (1998) 121-128
17. Iwanishi M., and Kobayashi M. Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 42 8 (1993) 1017-1021
18. Rosholt M.N., King P.A., and Horton E.S. High-fat diet reduces glucose transporter responses to both insulin and exercise. Am J Physiol 266 1 Part 2 (1994) R95-R101
19. Khoursheed M., Miles P.D., Gao K.M., Lee M.K., Moossa A.R., and Olefsky J.M. Metabolic effects of troglitazone on fat-induced insulin resistance in the rat. Metabolism 44 11 (1995) 1489-1494
20. Ghatta S., Srinivasan K., Kaul C.L., and Ramarao P. A study on alpha-adrenoceptor mediated contractile responses of high fat diet fed rat thoracic aorta. Pharmazie 60 2 (2005) 142-146
21. Folli F., Kahn C.R., Hansen H., Bouchie J.L., and Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100 9 (1997) 2158-2169
22. Kumar A.H., and Ramarao P. Saga of renin-angiotensin system and calcium channels in hypertensive diabetics: does it have a therapeutic edge?. Cardiovasc Drug Rev 23 2 (2005) 99-114
23. Rajagopalan S., Kurz S., Munzel T., Tarpey M., Freeman B.A., Griendling K.K., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97 8 (1996) 1916-1923
24. Amiri F., Venema V.J., Wang X., Ju H., Venema R.C., and Marrero M.B. Hyperglycemia enhances angiotensin II-induced Janus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 274 (1999) 32382-32386
25. Ciaraldi T.P., Gilmore A., Olefsky J.M., Goldberg M., and Heidenreich K.A. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism 39 10 (1990) 1056-1062
26. Hofmann C., Lorenz K., and Colca J.R. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology 129 4 (1991) 1915-1925
27. Way J.M., Harrington W.W., Brown K.K., Gottschalk W.K., Sundseth S.S., Mansfield T.A., et al. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142 3 (2001) 1269-1277
28. Shibasaki M., Takahashi K., Itou T., Bujo H., and Saito Y. A PPAR agonist improves TNF-alpha-induced insulin resistance of adipose tissue in mice. Biochem Biophys Res Commun 309 2 (2003) 419-424
29. Shimaya A., Noshiro O., Hirayama R., Yoneta T., Niigata K., and Shikama H. Insulin sensitizer YM268 ameliorates insulin resistance by normalizing the decreased content of GLUT4 in adipose tissue of obese Zucker rats. Eur J Endocrinol 137 6 (1997) 693-700
30. Shojima N., Sakoda H., Ogihara T., Fujishiro M., Katagiri H., Anai M., et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51 6 (2002) 1737-1744
31. Ferrannini E., Buzzigoli G., Bonadonna R., Giorico M.A., Oleggini M., Graziadei L., et al. Insulin resistance in essential hypertension. New Engl J Med 317 6 (1987) 350-357
32. Sowers J.R., and Bakris G.L. Antihypertensive therapy and the risk of type 2 diabetes mellitus. New Engl J Med 342 13 (2000) 969-970
33. Sowers J.R., Sowers P.S., and Peuler J.D. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 123 5 (1994) 647-652
34. Yoshioka S., Nishino H., Shiraki T., Ikeda K., Koike H., Okuno A., et al. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42 1 (1993) 75-80
35. Kemnitz J.W., Elson D.F., Roecker E.B., Baum S.T., Bergman R.N., and Meglasson M.D. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes 43 2 (1994) 204-211
36. Buchanan T.A., Meehan W.P., Jeng Y.Y., Yang D., Chan T.M., Nadler J.L., et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96 1 (1995) 354-360
37. Ogihara T., Rakugi H., Ikegami H., Mikami H., and Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 8 3 (1995) 316-320
38. Walker A.B., Chattington P.D., Buckingham R.E., and Williams G. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Diabetes 48 7 (1999) 1448-1453
39. Misurski D.A., Wu S.Q., McNeill J.R., Wilson T.W., and Gopalakrishnan V. Insulin-induced biphasic responses in rat mesenteric vascular bed: role of endothelin. Hypertension 37 5 (2001) 1298-1302
40. Reaven G.M., Lithell H., and Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. New Engl J Med 334 6 (1996) 374-381
41. Diep Q.N., El Mabrouk M., Cohn J.S., Endemann D., Amiri F., Virdis A., et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 105 19 (2002) 2296-2302
42. Takeda K., Ichiki T., Tokunou T., Funakoshi Y., Iino N., Hirano K., et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 102 15 (2000) 1834-1839
43. Imayama I., Ichiki T., Inanaga K., Ohtsubo H., Fukuyama K., Ono H., et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 72 (2006) 184-190
44. Kitazawa T., Eto M., Woodsome T.P., and Brautigan D.L. Agonists trigger G protein-mediated activation of the CPI-17 inhibitor phosphoprotein of myosin light chain phosphatase to enhance vascular smooth muscle contractility. J Biol Chem 275 14 (2000) 9897-9900
45. Zhang F., Sowers J.R., Ram J.L., Standley P.R., and Peuler J.D. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension 24 2 (1994) 170-175
46. Nakamura Y., Ohya Y., Onaka U., Fujii K., Abe I., and Fujishima M. Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br J Pharmacol 123 4 (1998) 675-682
47. Knock G.A., Mishra S.K., and Aaronson P.I. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes. Eur J Pharmacol 368 1 (1999) 103-109
48. Geng D.F., Wu W., Jin D.M., Wang J.F., and Wu Y.M. Effect of peroxisome proliferator-activated receptor gamma ligand. Rosiglitazone on left ventricular remodeling in rats with myocardial infarction. Int J Cardiol 113 1 (2006) 86-91